TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. L. AU - Torre, L. A. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 ID - Bray2018 ER - TY - JOUR AU - Kelly, S. P. AU - Anderson, W. F. AU - Rosenberg, P. S. AU - Cook, M. B. PY - 2018 DA - 2018// TI - Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States JO - Eur Urol Focus VL - 4 UR - https://doi.org/10.1016/j.euf.2017.10.014 DO - 10.1016/j.euf.2017.10.014 ID - Kelly2018 ER - TY - JOUR AU - Kirby, M. AU - Hirst, C. AU - Crawford, E. D. PY - 2011 DA - 2011// TI - Characterising the castration-resistant prostate cancer population: a systematic review JO - Int J Clin Pract VL - 65 UR - https://doi.org/10.1111/j.1742-1241.2011.02799.x DO - 10.1111/j.1742-1241.2011.02799.x ID - Kirby2011 ER - TY - JOUR AU - Ryan, C. J. AU - Smith, M. R. AU - Fizazi, K. AU - Saad, F. AU - Mulders, P. F. AU - Sternberg, C. N. PY - 2015 DA - 2015// TI - Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71205-7 DO - 10.1016/S1470-2045(14)71205-7 ID - Ryan2015 ER - TY - JOUR AU - Fizazi, K. AU - Scher, H. I. AU - Molina, A. AU - Logothetis, C. J. AU - Chi, K. N. AU - Jones, R. J. PY - 2012 DA - 2012// TI - Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70379-0 DO - 10.1016/S1470-2045(12)70379-0 ID - Fizazi2012 ER - TY - JOUR AU - Parker, C. C. AU - James, N. D. AU - Brawley, C. D. AU - Clarke, N. W. AU - Hoyle, A. P. AU - Ali, A. PY - 2018 DA - 2018// TI - Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial JO - Lancet VL - 392 UR - https://doi.org/10.1016/S0140-6736(18)32486-3 DO - 10.1016/S0140-6736(18)32486-3 ID - Parker2018 ER - TY - JOUR AU - Boeve, L. M. S. AU - Hulshof, M. AU - Vis, A. N. AU - Zwinderman, A. H. AU - Twisk, J. W. R. AU - Witjes, W. P. J. PY - 2019 DA - 2019// TI - Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial JO - Eur Urol VL - 75 UR - https://doi.org/10.1016/j.eururo.2018.09.008 DO - 10.1016/j.eururo.2018.09.008 ID - Boeve2019 ER - TY - JOUR AU - Dabestani, S. AU - Marconi, L. AU - Hofmann, F. AU - Stewart, F. AU - Lam, T. B. AU - Canfield, S. E. PY - 2014 DA - 2014// TI - Local treatments for metastases of renal cell carcinoma: a systematic review JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70235-9 DO - 10.1016/S1470-2045(14)70235-9 ID - Dabestani2014 ER - TY - JOUR AU - Bristow, R. E. AU - Tomacruz, R. S. AU - Armstrong, D. K. AU - Trimble, E. L. AU - Montz, F. J. PY - 2002 DA - 2002// TI - Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.20.5.1248 DO - 10.1200/JCO.2002.20.5.1248 ID - Bristow2002 ER - TY - JOUR AU - Glehen, O. AU - Mohamed, F. AU - Gilly, F. N. PY - 2004 DA - 2004// TI - Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia JO - Lancet Oncol VL - 5 UR - https://doi.org/10.1016/S1470-2045(04)01425-1 DO - 10.1016/S1470-2045(04)01425-1 ID - Glehen2004 ER - TY - JOUR AU - Ost, P. AU - Reynders, D. AU - Decaestecker, K. AU - Fonteyne, V. AU - Lumen, N. AU - Bruycker, A. PY - 2018 DA - 2018// TI - Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.4853 DO - 10.1200/JCO.2017.75.4853 ID - Ost2018 ER - TY - JOUR AU - Radwan, N. AU - Phillips, R. AU - Ross, A. AU - Rowe, S. P. AU - Gorin, M. A. AU - Antonarakis, E. S. PY - 2017 DA - 2017// TI - A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) JO - BMC Cancer VL - 17 UR - https://doi.org/10.1186/s12885-017-3455-6 DO - 10.1186/s12885-017-3455-6 ID - Radwan2017 ER - TY - JOUR AU - Siva, S. AU - Bressel, M. AU - Murphy, D. G. AU - Shaw, M. AU - Chander, S. AU - Violet, J. PY - 2018 DA - 2018// TI - Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial JO - Eur Urol VL - 74 UR - https://doi.org/10.1016/j.eururo.2018.06.004 DO - 10.1016/j.eururo.2018.06.004 ID - Siva2018 ER - TY - JOUR AU - Wei, X. X. AU - Ko, E. C. AU - Ryan, C. J. PY - 2017 DA - 2017// TI - Treatment strategies in low-volume metastatic castration-resistant prostate cancer JO - Curr Opin Urol VL - 27 UR - https://doi.org/10.1097/MOU.0000000000000436 DO - 10.1097/MOU.0000000000000436 ID - Wei2017 ER - TY - JOUR AU - Chi, K. N. AU - Kheoh, T. AU - Ryan, C. J. AU - Molina, A. AU - Bellmunt, J. AU - Vogelzang, N. J. PY - 2016 DA - 2016// TI - A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdv594 DO - 10.1093/annonc/mdv594 ID - Chi2016 ER - TY - JOUR AU - Khalaf, D. J. AU - Avilés, C. M. AU - Azad, A. A. AU - Sunderland, K. AU - Todenhöfer, T. AU - Eigl, B. J. PY - 2018 DA - 2018// TI - A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate JO - Can Urol Assoc J VL - 12 UR - https://doi.org/10.5489/cuaj.4600 DO - 10.5489/cuaj.4600 ID - Khalaf2018 ER - TY - JOUR AU - Azad, A. AU - Lester, R. AU - Leibowitz-Amit, R. AU - Joshua, A. M. AU - Heng, D. Y. C. AU - Eigl, B. J. PY - 2014 DA - 2014// TI - Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) JO - J Clin Oncol. VL - 32 UR - https://doi.org/10.1200/jco.2014.32.4_suppl.29 DO - 10.1200/jco.2014.32.4_suppl.29 ID - Azad2014 ER - TY - JOUR AU - He, L. AU - Liu, Y. AU - Han, H. AU - Liu, Z. AU - Huang, S. AU - Cao, W. PY - 2020 DA - 2020// TI - Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors JO - Am J Clin Oncol VL - 43 UR - https://doi.org/10.1097/COC.0000000000000622 DO - 10.1097/COC.0000000000000622 ID - He2020 ER - TY - JOUR AU - Lee, W. R. AU - Dignam, J. J. AU - Amin, M. B. AU - Bruner, D. W. AU - Low, D. AU - Swanson, G. P. PY - 2016 DA - 2016// TI - Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.0448 DO - 10.1200/JCO.2016.67.0448 ID - Lee2016 ER - TY - JOUR AU - Connor, M. J. AU - Shah, T. T. AU - Horan, G. AU - Bevan, C. L. AU - Winkler, M. AU - Ahmed, H. U. PY - 2019 DA - 2019// TI - Cytoreductive treatment strategies for de novo metastatic prostate cancer JO - Nat Rev Clin Oncol. VL - 17 UR - https://doi.org/10.1038/s41571-019-0284-3 DO - 10.1038/s41571-019-0284-3 ID - Connor2019 ER - TY - JOUR AU - Livi, L. AU - Detti, B. AU - Francolini, G. AU - Terziani, F. AU - Triggiani, L. AU - D'Angelillo, R. M. PY - 2019 DA - 2019// TI - Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence JO - Tumori VL - 105 UR - https://doi.org/10.1177/0300891619839282 DO - 10.1177/0300891619839282 ID - Livi2019 ER - TY - JOUR AU - Spratt, D. E. AU - Evans, M. J. AU - Davis, B. J. AU - Doran, M. G. AU - Lee, M. X. AU - Shah, N. PY - 2015 DA - 2015// TI - Androgen receptor upregulation mediates radioresistance after ionizing radiation JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-15-0892 DO - 10.1158/0008-5472.CAN-15-0892 ID - Spratt2015 ER - TY - JOUR AU - Polkinghorn, W. R. AU - Parker, J. S. AU - Lee, M. X. AU - Kass, E. M. AU - Spratt, D. E. AU - Iaquinta, P. J. PY - 2013 DA - 2013// TI - Androgen receptor signaling regulates DNA repair in prostate cancers JO - Cancer Discov VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-13-0172 DO - 10.1158/2159-8290.CD-13-0172 ID - Polkinghorn2013 ER - TY - JOUR AU - Detti, B. AU - D'Angelillo, R. M. AU - Ingrosso, G. AU - Olmetto, E. AU - Francolini, G. AU - Triggiani, L. PY - 2017 DA - 2017// TI - Combining abiraterone and radiotherapy in prostate cancer patients who progressed during abiraterone therapy JO - Anticancer Res VL - 37 ID - Detti2017 ER - TY - JOUR AU - Yildirim, B. A. AU - Onal, C. AU - Kose, F. AU - Oymak, E. AU - Sedef, A. M. AU - Besen, A. A. PY - 2019 DA - 2019// TI - Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate JO - Strahlenther Onkol VL - 195 UR - https://doi.org/10.1007/s00066-019-01429-6 DO - 10.1007/s00066-019-01429-6 ID - Yildirim2019 ER - TY - JOUR AU - Valeriani, M. AU - Marinelli, L. AU - Macrini, S. AU - Reverberi, C. AU - Aschelter, A. M. AU - Sanctis, V. PY - 2019 DA - 2019// TI - Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience JO - Radiat Oncol VL - 14 UR - https://doi.org/10.1186/s13014-019-1414-x DO - 10.1186/s13014-019-1414-x ID - Valeriani2019 ER - TY - JOUR AU - Giri, D. AU - Ozen, M. AU - Ittmann, M. PY - 2001 DA - 2001// TI - Interleukin-6 is an autocrine growth factor in human prostate cancer JO - Am J Pathol VL - 159 UR - https://doi.org/10.1016/S0002-9440(10)63067-2 DO - 10.1016/S0002-9440(10)63067-2 ID - Giri2001 ER - TY - JOUR AU - Sehgal, I. AU - Powers, S. AU - Huntley, B. AU - Powis, G. AU - Pittelkow, M. AU - Maihle, N. J. PY - 1994 DA - 1994// TI - Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer JO - Proc Natl Acad Sci U S A VL - 91 UR - https://doi.org/10.1073/pnas.91.11.4673 DO - 10.1073/pnas.91.11.4673 ID - Sehgal1994 ER - TY - JOUR AU - Brooks, E. D. AU - Chang, J. Y. PY - 2019 DA - 2019// TI - Time to abandon single-site irradiation for inducing abscopal effects JO - Nat Rev Clin Oncol VL - 16 UR - https://doi.org/10.1038/s41571-018-0119-7 DO - 10.1038/s41571-018-0119-7 ID - Brooks2019 ER - TY - STD TI - Berghen C, Joniau S, Ost P, Poels K, Everaerts W, Decaestecker K, et al. Progression-directed therapy for oligoprogression in castration-refractory prostate cancer. Eur Urol Oncol. 2019;23:S2588–9311(19)30138–5. ID - ref30 ER - TY - JOUR AU - Fujita, N. AU - Hatakeyama, S. AU - Momota, M. AU - Tobisawa, Y. AU - Yoneyama, T. AU - Ymamoto, H. PY - 2020 DA - 2020// TI - Safety and feasibility of radiation therapy to the primary tumor in patients with metastatic castration-resistant prostate cancer JO - Clin Genitourin Cancer VL - 18 UR - https://doi.org/10.1016/j.clgc.2020.03.009 DO - 10.1016/j.clgc.2020.03.009 ID - Fujita2020 ER - TY - JOUR AU - Barbastefano, J. AU - Garcia, J. A. AU - Elson, P. AU - Wood, L. S. AU - Lane, B. R. AU - Dreicer, R. PY - 2010 DA - 2010// TI - Association of percentage of tumor burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy JO - BJU Int VL - 106 UR - https://doi.org/10.1111/j.1464-410X.2010.09323.x DO - 10.1111/j.1464-410X.2010.09323.x ID - Barbastefano2010 ER - TY - JOUR AU - Spiliotis, J. AU - Halkia, E. AU - Lianos, E. AU - Kalantzi, N. AU - Grivas, A. AU - Efstathiou, E. PY - 2015 DA - 2015// TI - Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study JO - Ann Surg Oncol VL - 22 UR - https://doi.org/10.1245/s10434-014-4157-9 DO - 10.1245/s10434-014-4157-9 ID - Spiliotis2015 ER - TY - JOUR AU - Guckenberger, M. AU - Lievens, Y. AU - Bouma, A. B. AU - Collette, L. AU - Dekker, A. AU - deSouza, N. M. PY - 2020 DA - 2020// TI - Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation JO - Lancet Oncol VL - 21 UR - https://doi.org/10.1016/S1470-2045(19)30718-1 DO - 10.1016/S1470-2045(19)30718-1 ID - Guckenberger2020 ER -